Nanobody Market Analysis

Global Nanobody Market Overview

Nanobody Market size was valued at USD 0.65 billion in 2023. The nanobody market industry is projected to grow from USD 0.72 Billion in 2024 to USD 2.94 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 17.88% during the forecast period (2024 - 2032). The increasing prevalence of chronic diseases, rising demand for precision medicine, and increasing investment in nanobody research and development are driving market growth.

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Nanobody Market Trends

• The increasing prevalence of chronic diseases boosts market growth.

Nanobodies are small antibody fragments that have several advantages over traditional antibodies, such as greater stability, better tissue penetration, and reduced immunogenicity. The rising prevalence of autoimmune diseases and other chronic disorders demands the discovery of newer and more effective nanobody-based drugs for their treatment. For instance, in February 2019, the United States Food and Drug Administration (FDA) approved Cablivi (caplacizumab-yhdp), the first nanobody-based medicine of Sanofi S.A. (France), for adults with acquired thrombotic thrombocytopenic purpura (aTTP).

According to the World Health Organization (WHO), chronic diseases such as cancer, cardiovascular disease, and diabetes are responsible for 74% of all deaths globally. The incidence and prevalence of these diseases are expected to continue to rise, driven by factors such as aging populations, changing lifestyles, and increasing urbanization. Hence, the increasing prevalence of chronic diseases, combined with the unique advantages of nanobodies drives the market growth.

Nanobody Market Segment Insights

Nanobody Type Insights

The Nanobody Market segmentation, based on type, includes mono-specific and multi-specific. The mono-specific segment held the majority share in 2022 in the Nanobody Market revenue. This is due to the increasing prevalence of various types of cancer across the globe, the growing preference for personalized medicine, and the increase in investment and funding for clinical trials. Moreover, a monospecific nanobody is a protein or protein construct that contains at least one nanobody and is directed against a single Immuno-oncology target.

January 2023: Biocytogen (US) launched RenNano Mouse, a fully human heavy-chain antibody platform to accelerate nanobody drug discovery. The successful development of the RenNano platform expanded Biocytogen’s capabilities for antibody discovery and broadens the applications of our antibody library.

Nanobody Application Insights

The Nanobody Market segmentation is based on application that include therapeutic, diagnostic, and research. The therapeutic segment is further segmented into cancer, neurodegenerative diseases, infectious diseases, and others. Further, the diagnostic detection of protein and microorganisms, detection of small molecules, and imaging. The research segment has dominated the market in 2022 and the therapeutics segment is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is attributed to the increasing usage of nanobodies through pharmaceutical companies to research active drug molecules and the increasing prevalence of chronic diseases such as cancer, neurodegenerative diseases, infectious diseases, and joint-related diseases. For instance, as per the WHO, more than 55 million people across the globe have dementia, and more than 60% live in low- and middle-income countries (LMIC) as of March 2023. Hence, the wide range of applications of nanobodies to treat various types of cancer and infectious diseases and the fact that market players are investing and entering into agreements to develop nanobodies for diagnosis and treatment are positive factors contributing to the segment's growth.

Figure 2: NANOBODY MARKET SIZE, BY APPLICATION, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Nanobody End User Insights

The Nanobody Market segmentation is based on end user that includes pharmaceutical & biotechnology companies, research laboratories, and others. The pharmaceutical & biotechnological companies segment has dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to the increasing funding and investment to develop nanobodies, the rising use of nanobody platforms in pharmaceutical & biotechnological companies, and the rising preference for targeted therapies.  Additionally, nanobodies have become an essential tool for pharmaceuticals and biopharmaceutical companies for drug discovery. Companies are launching nanobody platforms to fulfill the needs of end users, such as pharmaceutical and biopharmaceutical companies.

February 2019: The U.S. Food and Drug Administration (FDA) approved Sanofi’s Cablivi (caplacizumab-yhdp), the first nanobody-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP). Cablivi is designed to stop the interaction of von Willebrand factor (vWF), a blood protein involved in hemostasis, with platelets.

Nanobody Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America nanobody market accounted for the largest market share in 2022. This is due to the high awareness associated with nanobodies technology in drug discovery and development to reduce the cost of production in the North American region. Companies such as Proteintech Group, Inc. (US), and Genscript Biotech Corporation (US) are actively working on improving nanobodies and fulfilling the demands of customers. The Genscript Biotech Corporation (US) offers comprehensive research and therapeutic nanobodies application services, and in several research studies, the company has provided lucrative growth opportunities.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: NANOBODY MARKET SIZE, BY REGION 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe nanobody market accounts for the second-largest market share due to the presence of active market players, growing nanobodies startups, and increasing prevalence of diseases such as infectious, neurological, and cancer. further, Germany nanobody market was attributed to hold the largest market share, and the France nanobody market is expected to fastest-growing market in the European region.

The Asia-Pacific nanobody market is expected to grow at a significant share from 2024 to 2032. This is due to the growing geriatric population, increasing prevalence of cancer and infectious diseases, and improving research capabilities in the Asia-Pacific region. Moreover, China nanobody market is expected to hold the largest market share, and India nanobody market is expected fastest-growing market in the Asia-Pacific region.

Furthermore, as per the National AIDS Control organization (NACO), approximately 62.97 thousand people were diagnosed with HIV infection, and 41.97 thousand deaths in India in 2021. According to the Integrated Health Information Platform, there were 3,038 influenza cases, including H3N2, in India till March 2023, and influenza is rapidly spreading in India. Thus, these factors are likely to have considerable growth for nanobody market.

The Rest of the World is segmented into the Middle East, Africa, and Latin America. The nanobody market in the above-mentioned regions is likely to witness growth due to the increasing prevalence of infectious diseases and the rising prevalence of non-communicable diseases. Moreover, the lack of knowledge associated with nanobody applications is also affecting the market's growth to some extent in these regions.

Nanobody Key Market Players & Competitive Insights

The Nanobody Market is characterized by the presence of many global, regional, and local vendors. Developments in the healthcare industry and growing research and development make the nanobody market lucrative. To expand their reach and optimize their operational costs, the major players focus on obtaining regulatory authorizations from government agencies for their products and emphasize acquisitions and product launches to gain a substantial market share. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as Sanofi (France), Merck KGaA (Germany), BIOCYTOGEN (US), and Proteintech Group, Inc (US) dominate the Nanobody Market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.

One of the primary business strategies adopted by manufacturers in the global nanobody industry to benefit clients and expand the nanobody market sector is to manufacture locally to reduce operating costs.

Merck KGaA (Germany) is a pharmaceutical company that offers a varied range of products subgrouped into three segments—healthcare, life sciences, and electronics. The company researches drugs in the areas of oncology and neurodegenerative as well as autoimmune and inflammatory diseases. The company is distributing its products in the following countries: China, India, Japan, Australia, Israel, United Arab Emirates, South Korea, Denmark, Italy, Netherlands, Spain, United Kingdom, Switzerland, Sweden, Argentina, Brazil, Canada, US, and New Zealand. For instance, in October 2020, Merck KGaA (Germany) announced that it has entered into an out-licensing agreement with Novartis AG (Switzerland), for the development of M6495, an anti-ADAMTS5 Nanobody for the

potential treatment of Osteoarthritis (OA).

Also, Sanofi (France) is a multinational pharmaceutical company that manufactures pharmaceutical products. The company offers drugs, generic medicines, and food supplements and provides medical devices for cancer, cardiology, gynecology, and diabetes. Sanofi's research and development efforts are concentrated on developing combination drugs to improve the efficacy of treatments and on developing novel biologic formulations to create precision medicines. Sanofi serves customers in more than 100 countries worldwide and more than 75 manufacturing sites in 70 countries. The company has about 20 R&D facilities across Europe, Asia, and North America.

Key Companies in the Nanobody Market include

• Sanofi (France)


• Merck KGaA (Germany)


• BIOCYTOGEN (US)


• Proteintech Group, Inc (US)


• Novartis AG (Switzerland)


• GenScript (US)


• Sensei Biotherapeutics, Inc (US)


• Beroni Group (Australia)


• ExeVir Bio (Belgium)


• Taisho Pharmaceutical Holdings Co., Ltd (Japan)


• DiosCURE Therapeutics SE (Germany)

Nanobody Industry Developments

August 2020: Beroni Group (Australia) announced a collaboration agreement with Genscript Biotech Corporation (US) for the development of a medical solution utilizing nanobody technology for COVID-19, particularly in leading pseudovirus neutralization test, humanization, and affinity maturation of nanobodies with the impartial of increasing the antibody affinity to target the antigen by five to ten-fold.

May 2020: Sensei Biotherapeutics, Inc (US) announced the acquisition of Alvaxa Biosciences (US) a camelid antibody therapeutics company. As per the agreement Sensei acquired camelid nanobody libraries which is expertise in nanobody discovery. Through this acquisition, the company boosts its business growth in the nanobody market.

Nanobody Market Segmentation

Nanobody Type Outlook

• Mono-Specific


• Multi-Specific

Nanobody Application Outlook

• Therapeutic
  
  
  
  • Cancer
  
  
  • Neurodegenerative Diseases
  
  
  • Infectious Diseases
  
  
  • Others
  
  
  
  


• Diagnostic
  
  
  
  • Detection Of Proteins and Microorganisms
  
  
  • Detection Of Small Molecules
  
  
  • Imaging
  
  
  
  


• Research

Nanobody End User Outlook

• Pharmaceutical & Biotechnology Companies


• Research Laboratories


• Others

Nanobody Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America